In CML, the CCN3 gene is down-regulated and its protein expression decreased as a direct consequence of the BCR-ABL tyrosine kinase activity, mediated at least in part by microRNAs 130a/b (McCallum et al. 2006; Suresh et al. 2011). The gene discussed is CCN3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.